It's been a rough year for the biotech industry, which as a whole has substantially lagged the broader market. Two worth a closer look today are Amgen (NASDAQ: AMGN) and Moderna (NASDAQ: MRNA) whose prospects really don't look as bad as their year-to-date performances suggest. At current levels, both Amgen and Moderna are worth investing in now.
Read full NASCAR article on Yahoo Sports
Read all NASCAR articles